Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,4 +4,12 @@
4	4
5	5	= Summary =
6	6
7		-
	7	+* AbbVie Inc. is a renowned biopharmaceutical company specialising in immunology, oncology, aesthetics, neuroscience, and eye care, selling drugs like Humira, Imbruvica, Rinvoq, Venclexta, and Mavyret/Maviret.
	8	+* The company was headquartered in North Chicago, Illinois, and was established in 2013 when it became a separate company from Abbott Laboratories.
	9	+* AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialisation and sale of innovative medicines and therapies.
	10	+* The 52-week price range of Abbvie is $177.01 to $178.49, the trailing PE ratio is 65.59, the gross margin is 62.42%, the operating margin is 23.49%, the net margin is 8.95%, and the return on assets is 3.61% as of 31 December 2023.
	11	+* The company's net revenues for 2023 decreased by 6.4% compared to the previous year, reaching $54,318 million. This decline was primarily due to economic pressures and direct biosimilar competition, while international revenues increased by 0.8%.
	12	+
	13	+= Brief Company Overview =
	14	+
	15	+AbbVie Inc. (NYSE: ABBV)is a globally recognised biopharmaceutical company with a strong presence in immunology, oncology, aesthetics, neuroscience, and eye care. The company sells Humira (adalimumab), Imbruvica (ibrutinib), Rinvoq (upadacitinib), Venclexta (venetoclax), Mavyret/Maviret (glecaprevir/pibrentasvir) and other drugs in support of immunology, oncology, aesthetics, neuroscience, and eye care. The company was headquartered in North Chicago, Illinois, and was established in 2013 when it became a separate company from Abbott Laboratories.